Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000393946

Medchemexpress LLC AZ-3137 | 2960179-55-7 | 99.9% | 801.87 | 5 MG
SDP

Catalog No. 5000393946
Encompass_Preferred

AZ'3137 is an orally active PROTAC-type androgen receptor (AR) degrader with a DC50 value of 22 nM. It can degrade L702H mutant AR (DC50 of 92 nM) and inhibit cell proliferation of LNCaP, with a GI50 value of 74 nM. It can also inhibit AR signaling and tumor growth in prostate cancer mice.

  • Orally active PROTAC-type androgen receptor (AR) degrader.
  • Degrades L702H mutant AR.
  • Inhibits cell proliferation of LNCaP cells.
  • Inhibits AR signaling and tumor growth in prostate cancer mice.
  • Inhibits AR signaling and cell proliferation of prostate cancer cell line LNCaP (0-10 μM; 7 days).
  • Inhibits the expression of AR target genes in LNCaP cells (0.1 nM-10 μM; 24 h) and degrades AR in C4-2 and VCAP cells (0.1 nM-10 μM; 24 h).
  • Inhibits tumor growth in prostate cancer mice (oral gavage (p.o.); once daily; for 10 days).

Catalog No. 50-003-93946 Supplier Medchemexpress LLC Supplier No. HY1627025MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

AZ'3137 is an orally active PROTAC-type androgen receptor (AR) degrader with a DC50 value of 22 nM. It can degrade L702H mutant AR (DC50 of 92 nM) and inhibit cell proliferation of LNCaP, with a GI50 value of 74 nM. It can also inhibit AR signaling and tumor growth in prostate cancer mice.

  • Orally active PROTAC-type androgen receptor (AR) degrader.
  • Degrades L702H mutant AR.
  • Inhibits cell proliferation of LNCaP cells.
  • Inhibits AR signaling and tumor growth in prostate cancer mice.
  • Inhibits AR signaling and cell proliferation of prostate cancer cell line LNCaP (0-10 μM; 7 days).
  • Inhibits the expression of AR target genes in LNCaP cells (0.1 nM-10 μM; 24 h) and degrades AR in C4-2 and VCAP cells (0.1 nM-10 μM; 24 h).
  • Inhibits tumor growth in prostate cancer mice (oral gavage (p.o.); once daily; for 10 days).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.